GSA Capital Partners’s Outlook Therapeutics OTLK Stock Holding History

GSA Capital Partners’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,319	Closed	-$190K	–	1967
2024 Q4	$190K	Buy	+100,319	New	+$413K	0.01%	1428
2023 Q4	–	Sell	-12,970	Closed	-$57K	–	1805
2023 Q3	$57K	Buy	+12,970	New	+$287K	﹤0.01%	1412
2023 Q2	–	Sell	-4,892	Closed	-$107K	–	1830
2023 Q1	$107K	Sell	4,892 -8,997	-65%	-$201K	0.01%	1349
2022 Q4	$300K	Buy	13,889 +5,498	+66%	+$120K	0.04%	932
2022 Q3	$205K	Buy	8,391 +140	+2%	+$3.25K	0.03%	1212
2022 Q2	$168K	Sell	8,251 -4,559	-36%	-$131K	0.03%	1115
2022 Q1	$456K	Buy	12,810 +2,308	+22%	+$72.1K	0.06%	598
2021 Q4	$286K	Buy	+10,502	New	+$375K	0.04%	964

Other funds holding OTLK

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GSA Capital Partners's OTLK Position: Q1 2025 in Review

GSA Capital Partners sold out of Outlook Therapeutics (OTLK) in Q1 2025, closing a stake of 100,319 shares — an estimated $190K sold.

GSA Capital Partners first reported a position in OTLK in Q4 2021 and held it in 8 quarters. The position peaked at $456K in Q1 2022. 63 funds tracked by Wall St. Rank hold OTLK as of Q1 2025.

GSA Capital Partners reported no remaining Outlook Therapeutics position as of Q1 2025 after selling out during the quarter.
GSA Capital Partners sold 100,319 Outlook Therapeutics shares in Q1 2025, an estimated $190K.
GSA Capital Partners first reported a position in Outlook Therapeutics in Q4 2021 and held it in 8 quarters.
GSA Capital Partners's Outlook Therapeutics position peaked at $456K in Q1 2022.
63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.